{"id":361338,"date":"2025-08-30T17:05:23","date_gmt":"2025-08-30T17:05:23","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-cullinan-therapeutics\/"},"modified":"2025-08-30T17:05:23","modified_gmt":"2025-08-30T17:05:23","slug":"how-to-buy-cullinan-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/","title":{"rendered":"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-361338","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Cullinan Therapeutics (CGEM) hisselerini g\u00fcncel fiyat\u0131 $7.66 ile nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin. Bu biyoteknoloji hissesi i\u00e7in yat\u0131r\u0131m stratejilerini, riskleri ve b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Cullinan Therapeutics (CGEM) hisselerini g\u00fcncel fiyat\u0131 $7.66 ile nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin. Bu biyoteknoloji hissesi i\u00e7in yat\u0131r\u0131m stratejilerini, riskleri ve b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"\u0130leri teknoloji biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Cullinan Therapeutics, otoimm\u00fcn ve kanser tedavilerinde heyecan verici bir s\u0131n\u0131r\u0131 temsil ediyor. Bu klinik a\u015famadaki biyofarma \u015firketi ya t\u0131bb\u0131 devrim niteli\u011finde de\u011fi\u015ftirebilir ya da sabr\u0131n\u0131z\u0131 s\u0131nayabilir\u2014i\u015fte bu y\u00fczden biyoteknoloji yat\u0131r\u0131m\u0131 bu kadar heyecan verici! CGEM'in portf\u00f6y\u00fcn\u00fczde olup olmamas\u0131 gerekti\u011fini birlikte ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130leri teknoloji biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Cullinan Therapeutics, otoimm\u00fcn ve kanser tedavilerinde heyecan verici bir s\u0131n\u0131r\u0131 temsil ediyor. Bu klinik a\u015famadaki biyofarma \u015firketi ya t\u0131bb\u0131 devrim niteli\u011finde de\u011fi\u015ftirebilir ya da sabr\u0131n\u0131z\u0131 s\u0131nayabilir\u2014i\u015fte bu y\u00fczden biyoteknoloji yat\u0131r\u0131m\u0131 bu kadar heyecan verici! CGEM'in portf\u00f6y\u00fcn\u00fczde olup olmamas\u0131 gerekti\u011fini birlikte ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Cullinan Therapeutics Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>30 A\u011fustos 2025 itibar\u0131yla Cullinan Therapeutics (CGEM) hissesi <strong>7,66 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize i\u015faretleyin: <strong>6 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014\u015firketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu raporlar fiyatlarda dramatik hareketlere neden olmu\u015ftur.<\/p> <p><strong>Kazan\u00e7 Raporlar\u0131 CGEM Hissesini Nas\u0131l Etkiler<\/strong><\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>7 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>7,93 $<\/td><td>%4,8 d\u00fc\u015f\u00fc\u015f (tahminlerin alt\u0131nda)<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>Klinik Veriler<\/td><td>8,50 $<\/td><td>%12 art\u0131\u015f (pozitif sonu\u00e7lar)<\/td><\/tr> <tr><td>\u015eub 2025<\/td><td>Ortakl\u0131k Haberi<\/td><td>9,80 $<\/td><td>%15 d\u00fc\u015f\u00fc\u015f (piyasa \u015f\u00fcphesi)<\/td><\/tr> <tr><td>Kas 2024<\/td><td>\u00d6nceki 3. \u00c7eyrek<\/td><td>10,20 $<\/td><td>%8 art\u0131\u015f (pipeline ilerlemesi)<\/td><\/tr> <tr><td>A\u011fu 2024<\/td><td>2. \u00c7eyrek 2024<\/td><td>11,50 $<\/td><td>%6 d\u00fc\u015f\u00fc\u015f (artan Ar-Ge harcamalar\u0131)<\/td><\/tr> <\/tbody> <\/table> <p>Model, CGEM'in klinik deneme sonu\u00e7lar\u0131 ve ortakl\u0131k duyurular\u0131na g\u00fc\u00e7l\u00fc tepki verdi\u011fini g\u00f6steriyor. Son A\u011fustos ay\u0131ndaki olumsuz sonu\u00e7 cesur yat\u0131r\u0131mc\u0131lar i\u00e7in al\u0131m f\u0131rsat\u0131 yaratt\u0131.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgalarla Dolu Bir S\u00fcr\u00fc\u015f<\/h2> <p>CGEM, Ocak'tan A\u011fustos 2025'e kadar \u00e7alkant\u0131l\u0131 bir seyir izledi:<\/p> <p><strong>Ocak 2025<\/strong>: 12,98 $ (tatil sonras\u0131 iyimserlik)<br\/> <strong>\u015eubat 2025<\/strong>: 10,70 $ (%19,6 d\u00fc\u015f\u00fc\u015f, ortakl\u0131k endi\u015feleri)<br\/> <strong>Mart 2025<\/strong>: 9,38 $ (%10,8 d\u00fc\u015f\u00fc\u015f, piyasa volatilitesi)<br\/> <strong>Nisan 2025<\/strong>: 8,10 $ (%1,85 art\u0131\u015f, hafif toparlanma)<br\/> <strong>May\u0131s 2025<\/strong>: 7,30 $ (%10 d\u00fc\u015f\u00fc\u015f, kazan\u00e7 beklentisi)<br\/> <strong>A\u011fustos 2025<\/strong>: 7,66 $ (g\u00fcncel seviye, 52 haftal\u0131k dip civar\u0131)<\/p> <p>D\u00fc\u015f\u00fc\u015f\u00fcn nedeni nedir? Biyoteknoloji hisseleri sekt\u00f6r genelinde bask\u0131 alt\u0131ndayd\u0131 ve CGEM'in artan Ar-Ge harcamalar\u0131 k\u0131sa vadeli yat\u0131r\u0131mc\u0131lar\u0131 korkuttu. Ancak s\u0131r \u015fu ki: klinik a\u015famadaki \u015firketler genellikle b\u00fcy\u00fck kataliz\u00f6rlerden \u00f6nce d\u00fc\u015f\u00fc\u015f ya\u015far.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p><strong>2025 Hedefi<\/strong>: 12-15 $ (Kas\u0131m verileri bekleniyor) \u2192 <strong>AL<\/strong><br\/> <strong>2026 Projeksiyonu<\/strong>: 18-22 $ (Olas\u0131 Faz 2 ba\u015far\u0131s\u0131)<br\/> <strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 25-30 $ (Olas\u0131 FDA ba\u015fvurular\u0131)<br\/> <strong>2030 Vizyonu<\/strong>: 35-40 $ (Ticarile\u015fme a\u015famas\u0131)<\/p> <p>Analistlerin ortak g\u00f6r\u00fc\u015f\u00fc f\u0131rsat \u00e7\u0131\u011fl\u0131\u011f\u0131 at\u0131yor\u2014ortalama fiyat hedefi 26,57 $ olup <strong>%247 y\u00fckseli\u015f potansiyeli<\/strong> anlam\u0131na geliyor! Yedi analist \"G\u00fc\u00e7l\u00fc Al\" derecelendirmesi verirken sat\u0131\u015f \u00f6nerisi yok.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2> <p><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/strong><\/p> <ul> <li><strong>Klinik ba\u015far\u0131s\u0131zl\u0131k riski<\/strong>: \u0130la\u00e7 adaylar\u0131n\u0131n %90'\u0131 ba\u015far\u0131s\u0131z olur<\/li> <li><strong>Nakit yak\u0131m\u0131<\/strong>: \u00c7eyreklik 70,1M $ zarar (<a href=\"https:\/\/www.biospace.com\/press-releases\/cullinan-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial-results\">2. \u00c7eyrek 2025 Sonu\u00e7lar\u0131<\/a>)<\/li> <li><strong>Hisse seyrelme riski<\/strong>: Daha fazla sermaye art\u0131r\u0131m\u0131 gerekebilir<\/li> <li><strong>Reg\u00fclasyon engelleri<\/strong>: FDA onay\u0131 belirsiz<\/li> <\/ul> <p><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/strong><\/p> <ul> <li><strong>510,9M $ nakit rezervi<\/strong> 2028'e kadar (<a href=\"https:\/\/www.stocktitan.net\/news\/CGEM\/cullinan-therapeutics-provides-corporate-update-and-reports-second-qtwpgjr5iemb.html\">G\u00fc\u00e7l\u00fc Bilan\u00e7o<\/a>)<\/li> <li><strong>\u00c7oklu kataliz\u00f6rler<\/strong>: IASLC WCLC ve ESMO Kongresi verileri<\/li> <li><strong>Yeni ortakl\u0131k<\/strong>: Genrix Bio'dan Velinotamig lisans\u0131<\/li> <li><strong>Analist g\u00fcveni<\/strong>: %100 al\u0131m derecelendirmesi (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/cullinan-therapeutics-inc-nasdaqcgem-given-average-rating-of-buy-by-analysts-2025-08-28\/\">MarketBeat Analizi<\/a>)<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-3'\u00fcn\u00fc y\u00fcksek riskli biyoteknolojiye ay\u0131r\u0131n<\/li> <li><strong>Kas\u0131m'\u0131 bekleyin<\/strong>: Kazan\u00e7 sonras\u0131 d\u00fc\u015f\u00fc\u015fler genellikle daha iyi giri\u015f noktalar\u0131 yarat\u0131r<\/li> <li><strong>\u00c7e\u015fitlendirin<\/strong>: CGEM'i yerle\u015fik sa\u011fl\u0131k hisseleriyle dengeleyin<\/li> <li><strong>Uyar\u0131lar kurun<\/strong>: Klinik deneme duyurular\u0131n\u0131 dikkatle takip edin<\/li> <\/ol> <p>Esprili bir yorum: \"CGEM ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014inan\u0131lmaz potansiyel ama bazen laboratuvarda ge\u00e7 saatlere kadar \u00e7al\u0131\u015f\u0131rken aramay\u0131 unutabilir!\"<\/p>  <h2>\u2705 Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir i\u015flem platformu se\u00e7in<\/td><td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Genellikle hisse senedi i\u015flemleri i\u00e7in 1-2 i\u015f g\u00fcn\u00fc s\u00fcrer<\/td><\/tr> <tr><td>3<\/td><td>Fon yat\u0131r\u0131n<\/td><td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"CGEM\" aramas\u0131 yap\u0131n<\/td><td>\u015eirket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Limit emirleri volatilite s\u0131ras\u0131nda a\u015f\u0131r\u0131 \u00f6deme yapman\u0131z\u0131 engeller<\/td><\/tr> <tr><td>6<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Komisyon \u00fccretlerini kontrol edin\u2014bir\u00e7ok platform $0 i\u015flem sunar<\/td><\/tr> <tr><td>7<\/td><td>Pozisyonu izleyin<\/td><td>Kazan\u00e7 ve klinik g\u00fcncellemeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2> <p>Pocket Option, yeni ba\u015flayanlar i\u00e7in hisse senedi eri\u015fimini kolayla\u015ft\u0131r\u0131r:<\/p> <ul> <li><strong>5 $ minimum depozito<\/strong>\u2014stratejileri d\u00fc\u015f\u00fck riskle test edin<\/li> <li><strong>1 belge KYC<\/strong>\u2014dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong>\u2014k\u00e2rlar\u0131n\u0131zda esneklik<\/li> <li><strong>Par\u00e7al\u0131 hisse imkan\u0131<\/strong>\u2014pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, biyoteknoloji volatilitesini yeni ba\u015flayanlar i\u00e7in daha az korkutucu hale getirir.<\/p>  <h2>\ud83c\udf0d 2025'te Cullinan Therapeutics: Pipeline G\u00fcc\u00fc<\/h2> <p>Cullinan, T-h\u00fccre ba\u011flay\u0131c\u0131 alan\u0131nda iki umut vadeden platformla \u00f6ne \u00e7\u0131k\u0131yor:<\/p> <ul> <li><strong>CLN-978<\/strong>: Lupus, artrit ve Sj\u00f6gren hastal\u0131\u011f\u0131 i\u00e7in Faz 1 denemeleri<\/li> <li><strong>Zipalertinib<\/strong>: Taiho Oncology ortakl\u0131\u011f\u0131 ile akci\u011fer kanseri tedavisi<\/li> <\/ul> <p>\u015eirketin <a href=\"https:\/\/www.directorstalkinterviews.com\/cullinan-therapeutics-cgem-stock-analysis-a-biotech-play-with-a-241-88-upside-potential\/4121213238\">modality-agnostic yakla\u015f\u0131m\u0131<\/a>, benzer teknolojiyle birden fazla hastal\u0131\u011f\u0131 hedeflemelerine olanak tan\u0131yor. Yakla\u015f\u0131k 450M $ piyasa de\u011feri, pipeline potansiyeline g\u00f6re d\u00fc\u015f\u00fck g\u00f6r\u00fcn\u00fcyor.<\/p> <p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025 y\u0131l\u0131nda Cullinan ara\u015ft\u0131rma ekibi, T-h\u00fccre ba\u011flay\u0131c\u0131 teknolojilerinin ayn\u0131 anda \u00fc\u00e7 otoimm\u00fcn hastal\u0131\u011f\u0131 tedavi edebilece\u011fini ke\u015ffetti\u2014t\u0131pta daha \u00f6nce hi\u00e7 ba\u015far\u0131lmam\u0131\u015f bir \u015fey!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Cullinan Therapeutics Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>30 A\u011fustos 2025 itibar\u0131yla Cullinan Therapeutics (CGEM) hissesi <strong>7,66 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize i\u015faretleyin: <strong>6 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014\u015firketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu raporlar fiyatlarda dramatik hareketlere neden olmu\u015ftur.<\/p>\n<p><strong>Kazan\u00e7 Raporlar\u0131 CGEM Hissesini Nas\u0131l Etkiler<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>7 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>7,93 $<\/td>\n<td>%4,8 d\u00fc\u015f\u00fc\u015f (tahminlerin alt\u0131nda)<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>Klinik Veriler<\/td>\n<td>8,50 $<\/td>\n<td>%12 art\u0131\u015f (pozitif sonu\u00e7lar)<\/td>\n<\/tr>\n<tr>\n<td>\u015eub 2025<\/td>\n<td>Ortakl\u0131k Haberi<\/td>\n<td>9,80 $<\/td>\n<td>%15 d\u00fc\u015f\u00fc\u015f (piyasa \u015f\u00fcphesi)<\/td>\n<\/tr>\n<tr>\n<td>Kas 2024<\/td>\n<td>\u00d6nceki 3. \u00c7eyrek<\/td>\n<td>10,20 $<\/td>\n<td>%8 art\u0131\u015f (pipeline ilerlemesi)<\/td>\n<\/tr>\n<tr>\n<td>A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek 2024<\/td>\n<td>11,50 $<\/td>\n<td>%6 d\u00fc\u015f\u00fc\u015f (artan Ar-Ge harcamalar\u0131)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Model, CGEM&#8217;in klinik deneme sonu\u00e7lar\u0131 ve ortakl\u0131k duyurular\u0131na g\u00fc\u00e7l\u00fc tepki verdi\u011fini g\u00f6steriyor. Son A\u011fustos ay\u0131ndaki olumsuz sonu\u00e7 cesur yat\u0131r\u0131mc\u0131lar i\u00e7in al\u0131m f\u0131rsat\u0131 yaratt\u0131.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgalarla Dolu Bir S\u00fcr\u00fc\u015f<\/h2>\n<p>CGEM, Ocak&#8217;tan A\u011fustos 2025&#8217;e kadar \u00e7alkant\u0131l\u0131 bir seyir izledi:<\/p>\n<p><strong>Ocak 2025<\/strong>: 12,98 $ (tatil sonras\u0131 iyimserlik)<br \/> <strong>\u015eubat 2025<\/strong>: 10,70 $ (%19,6 d\u00fc\u015f\u00fc\u015f, ortakl\u0131k endi\u015feleri)<br \/> <strong>Mart 2025<\/strong>: 9,38 $ (%10,8 d\u00fc\u015f\u00fc\u015f, piyasa volatilitesi)<br \/> <strong>Nisan 2025<\/strong>: 8,10 $ (%1,85 art\u0131\u015f, hafif toparlanma)<br \/> <strong>May\u0131s 2025<\/strong>: 7,30 $ (%10 d\u00fc\u015f\u00fc\u015f, kazan\u00e7 beklentisi)<br \/> <strong>A\u011fustos 2025<\/strong>: 7,66 $ (g\u00fcncel seviye, 52 haftal\u0131k dip civar\u0131)<\/p>\n<p>D\u00fc\u015f\u00fc\u015f\u00fcn nedeni nedir? Biyoteknoloji hisseleri sekt\u00f6r genelinde bask\u0131 alt\u0131ndayd\u0131 ve CGEM&#8217;in artan Ar-Ge harcamalar\u0131 k\u0131sa vadeli yat\u0131r\u0131mc\u0131lar\u0131 korkuttu. Ancak s\u0131r \u015fu ki: klinik a\u015famadaki \u015firketler genellikle b\u00fcy\u00fck kataliz\u00f6rlerden \u00f6nce d\u00fc\u015f\u00fc\u015f ya\u015far.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p><strong>2025 Hedefi<\/strong>: 12-15 $ (Kas\u0131m verileri bekleniyor) \u2192 <strong>AL<\/strong><br \/> <strong>2026 Projeksiyonu<\/strong>: 18-22 $ (Olas\u0131 Faz 2 ba\u015far\u0131s\u0131)<br \/> <strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 25-30 $ (Olas\u0131 FDA ba\u015fvurular\u0131)<br \/> <strong>2030 Vizyonu<\/strong>: 35-40 $ (Ticarile\u015fme a\u015famas\u0131)<\/p>\n<p>Analistlerin ortak g\u00f6r\u00fc\u015f\u00fc f\u0131rsat \u00e7\u0131\u011fl\u0131\u011f\u0131 at\u0131yor\u2014ortalama fiyat hedefi 26,57 $ olup <strong>%247 y\u00fckseli\u015f potansiyeli<\/strong> anlam\u0131na geliyor! Yedi analist &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecelendirmesi verirken sat\u0131\u015f \u00f6nerisi yok.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif \u0130\u015faretler<\/h2>\n<p><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/strong><\/p>\n<ul>\n<li><strong>Klinik ba\u015far\u0131s\u0131zl\u0131k riski<\/strong>: \u0130la\u00e7 adaylar\u0131n\u0131n %90&#8217;\u0131 ba\u015far\u0131s\u0131z olur<\/li>\n<li><strong>Nakit yak\u0131m\u0131<\/strong>: \u00c7eyreklik 70,1M $ zarar (<a href=\"https:\/\/www.biospace.com\/press-releases\/cullinan-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial-results\">2. \u00c7eyrek 2025 Sonu\u00e7lar\u0131<\/a>)<\/li>\n<li><strong>Hisse seyrelme riski<\/strong>: Daha fazla sermaye art\u0131r\u0131m\u0131 gerekebilir<\/li>\n<li><strong>Reg\u00fclasyon engelleri<\/strong>: FDA onay\u0131 belirsiz<\/li>\n<\/ul>\n<p><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/strong><\/p>\n<ul>\n<li><strong>510,9M $ nakit rezervi<\/strong> 2028&#8217;e kadar (<a href=\"https:\/\/www.stocktitan.net\/news\/CGEM\/cullinan-therapeutics-provides-corporate-update-and-reports-second-qtwpgjr5iemb.html\">G\u00fc\u00e7l\u00fc Bilan\u00e7o<\/a>)<\/li>\n<li><strong>\u00c7oklu kataliz\u00f6rler<\/strong>: IASLC WCLC ve ESMO Kongresi verileri<\/li>\n<li><strong>Yeni ortakl\u0131k<\/strong>: Genrix Bio&#8217;dan Velinotamig lisans\u0131<\/li>\n<li><strong>Analist g\u00fcveni<\/strong>: %100 al\u0131m derecelendirmesi (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/cullinan-therapeutics-inc-nasdaqcgem-given-average-rating-of-buy-by-analysts-2025-08-28\/\">MarketBeat Analizi<\/a>)<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-3&#8217;\u00fcn\u00fc y\u00fcksek riskli biyoteknolojiye ay\u0131r\u0131n<\/li>\n<li><strong>Kas\u0131m&#8217;\u0131 bekleyin<\/strong>: Kazan\u00e7 sonras\u0131 d\u00fc\u015f\u00fc\u015fler genellikle daha iyi giri\u015f noktalar\u0131 yarat\u0131r<\/li>\n<li><strong>\u00c7e\u015fitlendirin<\/strong>: CGEM&#8217;i yerle\u015fik sa\u011fl\u0131k hisseleriyle dengeleyin<\/li>\n<li><strong>Uyar\u0131lar kurun<\/strong>: Klinik deneme duyurular\u0131n\u0131 dikkatle takip edin<\/li>\n<\/ol>\n<p>Esprili bir yorum: &#8220;CGEM ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014inan\u0131lmaz potansiyel ama bazen laboratuvarda ge\u00e7 saatlere kadar \u00e7al\u0131\u015f\u0131rken aramay\u0131 unutabilir!&#8221;<\/p>\n<h2>\u2705 Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir i\u015flem platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Genellikle hisse senedi i\u015flemleri i\u00e7in 1-2 i\u015f g\u00fcn\u00fc s\u00fcrer<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;CGEM&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Limit emirleri volatilite s\u0131ras\u0131nda a\u015f\u0131r\u0131 \u00f6deme yapman\u0131z\u0131 engeller<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Komisyon \u00fccretlerini kontrol edin\u2014bir\u00e7ok platform $0 i\u015flem sunar<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Pozisyonu izleyin<\/td>\n<td>Kazan\u00e7 ve klinik g\u00fcncellemeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2>\n<p>Pocket Option, yeni ba\u015flayanlar i\u00e7in hisse senedi eri\u015fimini kolayla\u015ft\u0131r\u0131r:<\/p>\n<ul>\n<li><strong>5 $ minimum depozito<\/strong>\u2014stratejileri d\u00fc\u015f\u00fck riskle test edin<\/li>\n<li><strong>1 belge KYC<\/strong>\u2014dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong>\u2014k\u00e2rlar\u0131n\u0131zda esneklik<\/li>\n<li><strong>Par\u00e7al\u0131 hisse imkan\u0131<\/strong>\u2014pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, biyoteknoloji volatilitesini yeni ba\u015flayanlar i\u00e7in daha az korkutucu hale getirir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Cullinan Therapeutics: Pipeline G\u00fcc\u00fc<\/h2>\n<p>Cullinan, T-h\u00fccre ba\u011flay\u0131c\u0131 alan\u0131nda iki umut vadeden platformla \u00f6ne \u00e7\u0131k\u0131yor:<\/p>\n<ul>\n<li><strong>CLN-978<\/strong>: Lupus, artrit ve Sj\u00f6gren hastal\u0131\u011f\u0131 i\u00e7in Faz 1 denemeleri<\/li>\n<li><strong>Zipalertinib<\/strong>: Taiho Oncology ortakl\u0131\u011f\u0131 ile akci\u011fer kanseri tedavisi<\/li>\n<\/ul>\n<p>\u015eirketin <a href=\"https:\/\/www.directorstalkinterviews.com\/cullinan-therapeutics-cgem-stock-analysis-a-biotech-play-with-a-241-88-upside-potential\/4121213238\">modality-agnostic yakla\u015f\u0131m\u0131<\/a>, benzer teknolojiyle birden fazla hastal\u0131\u011f\u0131 hedeflemelerine olanak tan\u0131yor. Yakla\u015f\u0131k 450M $ piyasa de\u011feri, pipeline potansiyeline g\u00f6re d\u00fc\u015f\u00fck g\u00f6r\u00fcn\u00fcyor.<\/p>\n<p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025 y\u0131l\u0131nda Cullinan ara\u015ft\u0131rma ekibi, T-h\u00fccre ba\u011flay\u0131c\u0131 teknolojilerinin ayn\u0131 anda \u00fc\u00e7 otoimm\u00fcn hastal\u0131\u011f\u0131 tedavi edebilece\u011fini ke\u015ffetti\u2014t\u0131pta daha \u00f6nce hi\u00e7 ba\u015far\u0131lmam\u0131\u015f bir \u015fey!<\/p>\n"},"faq":[{"question":"Cullinan Therapeutics hisseleri nereden al\u0131n\u0131r?","answer":"Cullinan Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden CGEM sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"CGEM hissesinin riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, y\u00fcksek nakit yak\u0131m\u0131, hisse seyrelmesi ve FDA onay s\u00fcrecindeki belirsizlikler bulunmaktad\u0131r."},{"question":"Cullinan Therapeutics'in 2025 sonras\u0131 fiyat hedefi nedir?","answer":"Analistlerin ortalama fiyat hedefi 2025 i\u00e7in 12-15 $, 2026 i\u00e7in 18-22 $, 2028 i\u00e7in 25-30 $ ve 2030 i\u00e7in 35-40 $ aral\u0131\u011f\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayan biri CGEM hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131r\u0131n, Kas\u0131m ay\u0131ndaki kazan\u00e7 raporlar\u0131n\u0131 bekleyin, \u00e7e\u015fitlendirme yap\u0131n ve klinik geli\u015fmeleri yak\u0131ndan takip edin."},{"question":"Pocket Option platformu CGEM hissesi al\u0131m\u0131 i\u00e7in uygun mu?","answer":"Evet, Pocket Option d\u00fc\u015f\u00fck minimum depozito, kolay KYC s\u00fcreci, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve par\u00e7al\u0131 hisse al\u0131m imkan\u0131 sunarak yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Cullinan Therapeutics hisseleri nereden al\u0131n\u0131r?","answer":"Cullinan Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden CGEM sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"CGEM hissesinin riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, y\u00fcksek nakit yak\u0131m\u0131, hisse seyrelmesi ve FDA onay s\u00fcrecindeki belirsizlikler bulunmaktad\u0131r."},{"question":"Cullinan Therapeutics'in 2025 sonras\u0131 fiyat hedefi nedir?","answer":"Analistlerin ortalama fiyat hedefi 2025 i\u00e7in 12-15 $, 2026 i\u00e7in 18-22 $, 2028 i\u00e7in 25-30 $ ve 2030 i\u00e7in 35-40 $ aral\u0131\u011f\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayan biri CGEM hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131r\u0131n, Kas\u0131m ay\u0131ndaki kazan\u00e7 raporlar\u0131n\u0131 bekleyin, \u00e7e\u015fitlendirme yap\u0131n ve klinik geli\u015fmeleri yak\u0131ndan takip edin."},{"question":"Pocket Option platformu CGEM hissesi al\u0131m\u0131 i\u00e7in uygun mu?","answer":"Evet, Pocket Option d\u00fc\u015f\u00fck minimum depozito, kolay KYC s\u00fcreci, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve par\u00e7al\u0131 hisse al\u0131m imkan\u0131 sunarak yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-30T17:05:23+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-30T17:05:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/\",\"name\":\"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"datePublished\":\"2025-08-30T17:05:23+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-30T17:05:23+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-30T17:05:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/","name":"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","datePublished":"2025-08-30T17:05:23+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Cullinan Therapeutics, Inc. (CGEM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cullinan Therapeutics, Inc. (CGEM) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":361339,"slug":"how-to-buy-cullinan-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Cullinan Therapeutics, Inc. (CGEM) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Cullinan Therapeutics, Inc. (CGEM)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":361336,"slug":"how-to-buy-cullinan-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Cullinan Therapeutics, Inc. (CGEM) - Investimento em a\u00e7\u00f5es da Cullinan Therapeutics, Inc. (CGEM)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-cullinan-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/361338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=361338"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/361338\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334108"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=361338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=361338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=361338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}